Clinical Evaluation of SOLAMIN, was headed by Prof. H.A.B Coker, at Natural Medicine and
Molecular Pharmaco-Biotechnology Laboratories – College of Medicine, University of Lagos, Nigeria, at the instance of former Minister of Health, Prof. Eyitayo Lambo, and released at Nigerian
Institute of Medical Research, Yaba, Lagos, in August, 2006.
Results obtained in the study showed that SOLAMIN demonstrated sickling prevention and sickling reversal activities when incubated with hbss erythrocytes within the concentration range 0.25mg/ml – 0.5mg/ml. Average or percentage sickling inhibition of 89.56 – 97.95% was obtained using extract concentration of 0.25mg/ml – 5.0mg/ml, whilst the same concentration range gave 63.82 – 84.00% sickling reversal.
SOLAMIN, with NAFDAC registration number A7-1090L, when administered on patients, greatly
enhanced the physical development and totally eliminated the fragile nature of sicklers. Patients also recorded good and remarkable PCV and HB levels.
Complete elimination of crisis
Enhanced physical development with total elimination of fragile look/nature
Cures leg ulcer
Found to be very safe for consumption, with no negative side effect, even after years of use
No need for routine drugs such as Paludrine, B. Com, Multivitamins, etc, while on SOLAMIN
(A feat yet to be attained by any known management therapy in the world).
The findings on SOLAMIN make it to be ahead of any known management therapy for sickle cell anaemia
in the world.